Home>Topics>Companies>Barr Pharmaceuticals

Barr Pharmaceuticals BRL

  1. All
  2. Commentary
  3. Headlines
    1. Stockton is Bankrupt: Now What?

      Headlines

      Thu, 11 Apr 2013

      raises questions about the broader implications of the practice for the generic drug industry. Analyst Report: Barr Pharmaceuticals BRL Analyst Report: Dr. Reddy Laboratories RDY Analyst Report: Merck Analyst Report: Mylan Technologies MYL

    2. What Maslow and Rand Would Tell Investors Today

      Headlines

      Tue, 2 Apr 2013

      We're placing Barr Pharmaceuticals BRL under review while we evaluate the company's decision, announced Tuesday, to acquire Pliva. Barr is paying $2.2 billion

    3. Teva May Postpone Barr Acquisition

      Commentary

      Thu, 9 Oct 2008

      We're maintaining our fair value estimate for Barr Pharmaceuticals BRL at Teva's TEVA negotiated acquisition price of $67 per share despite a breakdown in the commercial paper market that could make

    4. Par under Review

      Commentary

      Fri, 8 Aug 2008

      in these areas take the steam out of any near-term growth. It's also a sign of the company's inability to compete effectively against the larger, more efficient, U.S. generic competitors like Mylan MYL, Barr BRL , and Teva TEVA.

    5. Strong 2Q for Mylan

      Commentary

      Wed, 6 Aug 2008

      generic oral contraceptives in 2010; this pact would shake up the longstanding generic oral contraceptives duopoly between Barr BRL and Watson WPI. The pending acquisition of Barr by Teva TEVA announced last quarter consolidates two major global competitors

    6. Teva Agrees to Buy Barr

      Commentary

      Fri, 18 Jul 2008

      Teva Pharmaceutical TEVA agreed Friday to buy Barr Pharmaceuticals BRL for $67 per share. We're bringing Barr's fair value estimate in line with the purchase price, as we believe the deal will

    7. Rumored Barr-Teva Combo Makes Sense

      Commentary

      Thu, 17 Jul 2008

      Barr Pharmaceuticals ' BRL stock price rose 20% today on rumors of a potential buyout from Teva TEVA. While unconfirmed by either party, the proposed price

    8. Barr under Review

      Commentary

      Thu, 8 May 2008

      We're placing Barr Pharmaceuticals ' BRL fair value estimate under review following Thursday's disappointing first-quarter results. We expect to decrease our fair

    9. Barr Wins Major Patent Challenge

      Commentary

      Tue, 4 Mar 2008

      Barr Pharmaceuticals BRL pleased investors March 3 with a favorable court ruling against Bayer Schering; Barr successfully challenged the patent for Bayer

    10. Cephalon Delivers Respectable 4Q

      Commentary

      Wed, 13 Feb 2008

      a 22% decline in Cephalon's pain franchise. We think Actiq sales will erode rapidly in 2008 and 2009 as Barr Pharmaceuticals ' BRL generic alternative gains market share. However, we expect Fentora sales for cancer pain as well as expected

    « Prev123Next »
    Content Partners